From: ITGA5 is a prognostic biomarker and correlated with immune infiltration in gastrointestinal tumors
Clinicopathological characteristics | Overall survival (n = 875) | Progression free survival (n = 640) | ||||
---|---|---|---|---|---|---|
N | Hazard ratio | P-value | N | Hazard ratio | P-value | |
Gender | ||||||
Female | 236 | 2.74 (1.68–4.46) | 2.6e-05 | 201 | 2.69 (1.58–4.58) | 0.00014 |
Male | 544 | 2.75 (2.12–3.57) | 2.2e-15 | 437 | 2.55 (2.00–3.25) | 4.2e-15 |
Stage | ||||||
1 | 67 | 3.62 (1.00–13.12) | 0.036 | 60 | 2.42 (0.63–9.31) | 0.19 |
2 | 140 | 2.18 (1.09–4.33) | 0.023 | 131 | 1.96 (0.98–3.90) | 0.051 |
3 | 305 | 2.31 (1.61–3.30) | 2.4e-06 | 186 | 1.87 (1.29–2.72) | 8e-04 |
4 | 148 | 1.78 (1.2–2.64) | 0.0039 | 141 | 1.60 (1.07–2.38) | 0.02 |
Stage T | ||||||
2 | 241 | 2.00 (1.29–3.11) | 0.0015 | 239 | 1.98 (1.26–3.11) | 0..0024 |
3 | 204 | 1.73 (1.19–2.51) | 0.0036 | 204 | 1.37 (0.98–1.91) | 0.065 |
4 | 38 | 2.73 (1.10–6.75) | 0.025 | 39 | 3.39 (1.37–8.40) | 0.0054 |
Stage N | ||||||
0 | 74 | 1.92 (0.82–4.46) | 0.13 | 72 | 1.95 (0.85–4.49) | 0.11 |
1 | 225 | 3.13 (1.99–4.94) | 2.3e-07 | 222 | 2.84 (1.83–4.42) | 1.2e-06 |
2 | 121 | 2.56 (1.62–4.05) | 3.1e-05 | 125 | 2.08 (1.33–3.25) | 0.00098 |
3 | 76 | 2.1 (1.22–3.61) | 0.0061 | 76 | 1.84 (1.02–3.33) | 0.04 |
1 + 2 + 3 | 422 | 2.14 (1.64–2.80) | 9.8e-09 | 423 | 2.30 (1.66–3.20) | 2.8e-07 |
Stage M | ||||||
0 | 444 | 2.31 (1.66–3.21) | 2.6e-07 | 443 | 2.12 (1.55–2.91) | 1.6e-06 |
1 | 56 | 2.66 (1.45–4.88) | 0.0011 | 56 | 1.69 (0.92–3.12) | 0.088 |
Lauren classification | ||||||
Intestinal | 320 | 2.84 (2.07–3.90) | 1.6e-11 | 263 | 2.70 (1.74–4.20) | 4.2e-06 |
Diffuse | 241 | 2.00 (1.33–2.99) | 0.00061 | 231 | 2.10 (1.33–3.32) | 0.0012 |
Mixed | 32 | 1.88 (0.68–5.20) | 0.22 | 28 | 0.48 (0.17–1.35) | 0.16 |
Differentiation | ||||||
Poor | 165 | 0.75 (0.50–1.12) | 0.16 | 121 | 1.39 (0.79–2.45) | 0.25 |
Moderate | 67 | 2.16 (1.08–4.30) | 0.025 | 67 | 2.23 (1.15–4.32) | 0.015 |